GlassScriptPhysician profile
Steven H Kahn
NPI 1164461356
$19,611.07
in general payments reported to CMS, 2019-2025
37 companies · $443 in 2025
The $443 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,249 · 2020: $91.08 · 2021: $25.93 · 2022: $1,677 · 2023: $12K · 2024: $935 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,200 · Travel and Lodging: $3,064 · Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,200.00 |
| Travel and Lodging | $3,064.33 |
| Food and Beverage | $2,303.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Think Surgical, INC. | $11,401.70 | 2023 | |
| Ethicon INC. | $2,040.00 | 2019-2022 | |
| Orthogenrx INC. | $2,000.21 | 2019 | |
| Stryker Corporation | $1,461.20 | 2019-2025 | Mako, Insignia, Triathlon |
| Zimmer Biomet Holdings, INC. | $817.88 | 2019-2023 | Explor |
| Zoll Medical Corporation | $360.00 | 2022 | |
| Progenacare Global, LLC | $273.24 | 2023 | |
| Depuy Synthes Sales INC. | $164.52 | 2019-2024 | Dynacord, Truespan Orthocord, Monovisc |
| Collegium Pharmaceutical, INC. | $161.56 | 2019-2024 | Xtampza, Belbuca |
| Pacira Pharmaceuticals Incorporated | $124.99 | 2024 | Exparel |
| Fidia Pharma USA INC. | $76.80 | 2019 | |
| Eclipse Technology Solutions INC. | $70.29 | 2023 | |
| Medacta USA, INC. | $57.85 | 2023 | Gmk Efficiency |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.04 | 2024 | Relistor |
| Davol INC. | $47.47 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $39.60 | 2023 | Xeomin |
| Abbott Laboratories | $38.29 | 2019-2022 | |
| Avanos Medical | $38.26 | 2022 | |
| Dynasplint Systems INC. | $38.00 | 2019 | |
| Merz North America, INC. | $36.72 | 2019 | |
| Si-Bone, INC. | $35.08 | 2024 | |
| Nevro Corp. | $31.63 | 2019 | |
| Pacira Therapeutics, INC. | $28.21 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $25.91 | 2019-2020 | |
| Assertio Therapeutics, INC. | $25.50 | 2019-2020 | |
| Convatec INC. | $20.62 | 2020 | |
| Medtronic, INC. | $19.35 | 2024 | Intellis Adaptivestim |
| Smith+Nephew, INC. | $16.56 | 2024 | Healicoil, Bone Anchors With Arthroscopic Delivery System, Spatial Frame |
| Kci USA, INC. | $14.49 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.35 | 2022 | |
| Ibsa Pharma INC. | $13.87 | 2023 | Tirosint, Licart |
| Linkbio Corp | $13.62 | 2025 | |
| Bioventus LLC | $13.47 | 2019 | |
| Horizon Therapeutics Plc | $11.97 | 2020 | |
| Trice Medical, INC. | $11.34 | 2019 | |
| Zyla Life Sciences, INC. | $10.89 | 2019 | |
| Heraeus Medical, LLC. | $6.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.